Other attributes
JUNE LEE is a physician, scientist and a respected leader. June is recognized for her ability integrate the emerging advances in science with the driving strategy of the business. With a valuable set of experiences spanning leadership roles in early and late phase drug development at Genentech, academic translational research at UCSF advancing early stage product development and innovative public-private partnerships, June is able to make both people and ideas connections across traditional boundaries of academia and industry as well as early phase discovery through commercialization. She has a track record of building and empowering high-quality teams and effective people development. She is big picture thinking and solution oriented.
Most recently, as the EVP and Chief Development Officer of MyoKardia, a clinical stage public biotechnology company with a focus on precision cardiovascular drug development, June led the building of MyoKardia’s world class development organization. Since joining MyoKardia in early 2017, she has driven portfolio strategy, led clinical and non-clinical development, and has overseen quality and manufacturing organizations and successfully transformed MyoKardia into a high performance research and development organization currently in pivotal registrational phase moving towards commercialization.
Prior to MyoKardia, June was a Professor of Medicine at UCSF School of Medicine, where she served as Director of Translational Research and built the Catalyst Program, an internal accelerator at UCSF for early stages technologies in therapeutics, devices, diagnostics, and digital health. She is also the founding chair of University of California Drug, Device, Discovery and Development Group. Previously, she was the therapeutic area head in early clinical development in cardiovascular, metabolism, respiratory, and infectious diseases at Genentech. June serves on the Board of Directors for the Council of Korean Americans and served previously as the Chair. She has served as a founding member of the Translational Research Advisory Council of the MOGAM Research Institute, and the MTRAC for Life Sciences Innovation Hub Therapeutic/Diagnostic Oversight Committee, a unit associated with The University of Michigan Medical School.
She currently serves on the SAB for Aer Therapeutics and Foresite Labs.
